|
Naviscan partners with leading hospitals and universities to conduct clinical trials and other research pertaining to PEM. Patients interested in participating in a research study are encouraged to contact the hospital/university directly, using the provided links and/or contact information below. Current Research/Trials
The purpose of this study is to compare the value of FDG Positron Emission Mammography (PEM) with contrast enhanced Magnetic Resonance Imaging (MRI) of the breast for patients with breast cancer. This study will also perform a special pathology.test to compare the FDG PEM and contrast enhanced breast MRI images with the results from the standard of care breast surgery. This may teach us more about the biology of each breast tumor.
The purpose of this study is to determine optimal, lowest dose of radioactive tracer required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating breast conserving surgery but identified to have a second unsuspected breast cancer by MRI. Study Center
This study seeks to evaluate the ability to perform breast biopsies using positron emission mammography (PEM) and the Stereo Navigator biopsy guidance accessory to determine if PEM and Stereo Navigator help obtain results in fewer clinical visits than if magnetic resonance imaging (MRI), mammography and/or ultrasound are utilized. Study Center
This study seeks to determine whether or not the PEM scanner can be used to determine response to neoadjuvant chemotherapy in patients earlier in the cycle than with contrast-enhanced breast MRI. Study Center
This study seeks to evaluate if the Naviscan PEM scanner can assess Axillary Lymph Node involvement preoperatively in patients with newly diagnosed breast cancer and to compare the results with bilateral breast MRI and/or axillary ultrasound. Study Center
This study seeks to enroll women who are scheduled to undergo a screening mammogram and have either dense breast tissue, are at high risk for breast cancer and are from one of the following ethnic backgrounds: Hispanic, Haitian Creole, African American or Caucasian. Participants will undergo a conventional two-view mammogram and positron emission mammography (PEM) scan. Immediately following imaging, patients are asked to complete a questionnaire on their impression of a standard mammogram versus PEM. The purpose of this study is to compare PEM to mammography for the detection of malignant lesions in women with dense breast tissue and/or who are at high risk of breast cancer. Study Center
Boston Medical Center
Select Recent Abstracts Yang WT, Rohren E, Mawlawi O, Krishnamurphy S, Wei W, Cristofanilli M, Lucci A, Buchholz T. Functional Evaluation of Response to Targeted Therapy in HER2 Over Expressing Inflammatory Breast Cancer (IBC) Patients Using Positron Emission Mammography.. Presented at the American Association of Cancer Research 101st Annual Meeting, April, 2010 R Parbhu, MD, M Hayes, MD, Radiology Associates of Hollywood, Memorial Healthcare System, Hollywood, FL. Integration of Positron Emission Mammography (PEM) in a Clinical Breast Center. Presented at the 20th Annual National Interdisciplinary Breast Center Conference, March 2010. K Schilling, MD, Boca Raton, FL, D Narayanan, MS, JE Kalinyak, MD, PhD. PET-Guided Biopsy: A Case Study. Presented at the 19th Annual National Interdisciplinary Breast Center Conference, March, 2009. Schilling K, Mayberry J, Rai R, Luo W, Kalinyak JE, Berg W, Dupree B, Shusterman DK, Gittleman M, Narayanan D et al.Positron Emission Mammography Guided Breast Biopsy. Presented at the 94th Annual Meeting of the Radiological Society of North America, November 2008. Schilling K, Narayanan MS, Kalinyak JE. Multimodality Effect of Breast Density, Menopausal Status And Hormone Use in High Resolution Positron Emission Mammography. Presented at the 94th Annual Meeting of the Radiological Society of North America, November 2008. Jang S , Adler L, Paccapaniccia A, Luo J, Sternick E, Wazer D. Evaluation of Positron Emission Mammography (PEM) and PET/CT Imaging in Breast Cancer. Presented at World Molecular Imaging Congress, September 2008. Velasquez M. High-Resolution Positron Emission Mammography in Breast Cancer Management. Presented at the 4th Inter-American Breast Cancer Conference, July 2008. Schilling K. High Resolution Positron Emission Mammography: Utility in Presurgical Planning for Breast Cancer Patients.Presented at Society of Nuclear Medicine Annual Meeting, June 2008. Berg WA, Naraayanan D, Kalinyak JE, Zavarzin V. Interpretation of Positron Emission Mammography (PEM) by Experienced Breast Imaging Radiologists: Comparison to MRI. Presented at the 93rd Annual Meeting of the Radiological Society of North America, November 2007. Adler L, Narayanan D, et al. Quantitative improvement in breast lesion detectability on delayed images using high resolution positron emission mammography. Presented at Society of Nuclear Medicine Annual Meeting, June 2007. Thurmond AS, Scanlan CK, Richmond JA, Warnock GL, et al. Size and Extent of Breast Cancer: Comparison of Mammography, MRI, and Positron Emission Mammography (PEM) in Women with Core Biopsy Diagnosis. Presented at National Consortium of Breast Centers Annual Meeting, March 2007. |
.jpg){kind=small}
